{"entity":{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","aka":[],"tldr":"Ananya Choudhury is a clinical oncologist developing biomarker-guided radiotherapy for bladder cancer.","summary":"Ananya Choudhury is Professor of Clinical Oncology at the University of Manchester and a consultant at The Christie NHS Foundation Trust. Her specialisms are bladder cancer radiotherapy, hypoxia biomarkers and radiobiology, using modern image-guided external beam techniques. She is known for developing biomarker-guided radiotherapy for bladder cancer, including hypoxia signatures that select patients for radiosensitisation. Her papers include an individual patient data meta-analysis of hypofractionated radiotherapy in the BC2001 and BCON trials, a phase II study of hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer, and a study of pre-treatment lymphocytopaenia as an adverse prognostic marker. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choudhury%20A%5BAuthor%5D%20bladder%20radiotherapy%20hypoxia"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Oncology, University of Manchester; Consultant, The Christie","institutionId":"the-christie","specialisms":["Bladder cancer radiotherapy","Hypoxia biomarkers","Radiobiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choudhury%20A%5BAuthor%5D%20bladder%20radiotherapy%20hypoxia"}],"papers":[{"title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(20)30607-0"},{"title":"Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer","journal":"Journal of Clinical Oncology","year":2011,"doi":"10.1200/jco.2010.31.5721"},{"title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdv546"}]},"route":"/people/ananya-choudhury/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"institution":[{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"idea":[{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/"}]}}